Some markets are more difficult to gather detailed information from, and the Italian market falls in that category. That means that when we do run analytics on the market, it's important to share!
- 1,482 parallel trade licenses have been granted to bring stock into Italy, though 248 are no longer commercialised.
- 17 different companies hold these licenses. GMM Farma being the biggest with 269 licenses approved, including 24 licenses granted in 2024.
- Bayer's oral contraceptive Yasmin is the most contested parallel import product, with 12 different companies holding PI licenses for this.
- Of the 223 different products imported (that is, excluding different strengths and pack size variations), 67 are held by a single company without competition.
- In line with the wider PI industry, the number of licenses granted per quarter has increased steadily over the last 10 years. From an average of 9.75 licenses per quarter in 2013, to 48 per quarter in 2023.
The rise in competition for parallel import products, and the growth in the industry more broadly, has resulted in companies looking for a new 'edge' that allows them to compete more effectively. Pharma Footpath has been working with parallel import companies to identify new opportunities before others, and track competition more effectively.
If you're interested in seeing what data analytics we can provide for your business, you can reply to this message and let me know what you're keen to learn more about!
Phil
pharma footpath
